MDT-AP-0825
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 156
- os_event
- false
- age_years
- 21
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.931098628
- umap2_2d
- -11.41461898
- umap1_3d
- -3.374504156
- umap2_3d
- 0.040658511
- umap3_3d
- 6.454515774
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.480
- ALLOGRAFT_REJECTION+0.410
- MYC_TARGETS_V2+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- IL6_JAK_STAT3_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.340
- APOPTOSIS+0.320
- COAGULATION+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.270
- SPERMATOGENESIS-0.220
- TGF_BETA_SIGNALING-0.210
- HEME_METABOLISM-0.190
- PANCREAS_BETA_CELLS-0.110
- ANDROGEN_RESPONSE-0.100
- G2M_CHECKPOINT-0.090
- UV_RESPONSE_DN-0.080
- PI3K_AKT_MTOR_SIGNALING-0.070
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0348 | Med | Medulloblastoma | 0.848 |
| 2 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.828 |
| 3 | DRR168610 | — | — | 0.825 |
| 4 | BS_D8N31T39 | low-grade glioma | — | 0.819 |
| 5 | MDT-AP-1196 | Med | Medulloblastoma | 0.818 |
| 6 | TCGA-BH-A0BZ-01A-31R-A12P-07 | — | C | 0.808 |
| 7 | TCGA-FD-A6TD-01A-51R-A33J-07 | — | — | 0.807 |
| 8 | TCGA-63-A5MT-01A-21R-A26W-07 | — | cohortSQ1 | 0.800 |
| 9 | TCGA-GU-A766-01A-11R-A32O-07 | — | — | 0.795 |
| 10 | R317 | — | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |